AgeX Therapeutics Alpha and Beta Analysis
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as AgeX Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in AgeX Therapeutics over a specified time horizon. Remember, high AgeX Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to AgeX Therapeutics' market risk premium analysis include:
Beta (0.15) | Alpha 0.56 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
AgeX |
AgeX Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. AgeX Therapeutics market risk premium is the additional return an investor will receive from holding AgeX Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AgeX Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate AgeX Therapeutics' performance over market.| α | 0.56 | β | -0.15 |
AgeX Therapeutics Fundamentals Vs Peers
Comparing AgeX Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze AgeX Therapeutics' direct or indirect competition across all of the common fundamentals between AgeX Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as AgeX Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of AgeX Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing AgeX Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare AgeX Therapeutics to competition |
| Fundamentals | AgeX Therapeutics | Peer Average |
| Return On Asset | -0.82 | -0.14 |
| Operating Margin | (63.57) % | (5.51) % |
| Current Valuation | 33.33 M | 16.62 B |
| Shares Outstanding | 2.5 M | 571.82 M |
| Shares Owned By Insiders | 75.73 % | 10.09 % |
| Shares Owned By Institutions | 5.64 % | 39.21 % |
| Number Of Shares Shorted | 4.47 K | 4.71 M |
AgeX Therapeutics Opportunities
AgeX Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About AgeX Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including AgeX or other delisted stocks. Alpha measures the amount that position in AgeX Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
AgeX Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of AgeX Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AgeX Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of AgeX Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of AgeX Therapeutics. Please utilize our Beneish M Score to check the likelihood of AgeX Therapeutics' management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with AgeX Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |